Shares of I-Mab (NASDAQ:IMAB) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus target price of $16.00 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also given I-Mab an industry rank of 33 out of 254 based on the ratings given to its competitors.
IMAB has been the subject of a number of research analyst reports. CICC Research initiated coverage on shares of I-Mab in a research report on Thursday, February 13th. They set an “outperform” rating and a $18.09 price objective for the company. China Renaissance Securities initiated coverage on shares of I-Mab in a research report on Wednesday, February 12th. They set a “buy” rating and a $17.93 price objective for the company. Finally, ValuEngine raised shares of I-Mab from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd.
IMAB stock traded down $0.63 during mid-day trading on Monday, hitting $24.11. 419 shares of the company were exchanged, compared to its average volume of 90,546. The company has a market cap of $1.41 billion and a price-to-earnings ratio of -0.86. The business has a 50 day simple moving average of $19.47. I-Mab has a 1-year low of $9.30 and a 1-year high of $32.89.
I-Mab (NASDAQ:IMAB) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($17.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.11 million for the quarter. On average, analysts predict that I-Mab will post -2.25 earnings per share for the current fiscal year.
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases.
Further Reading: Is it better to buy a fund with a higher or lower NAV?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.